These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Matassov D, Cupo A, Galarza JM. Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114 [Abstract] [Full Text] [Related]
29. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745 [Abstract] [Full Text] [Related]
30. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design. Liu WC, Liu YY, Chen TH, Liu CC, Jan JT, Wu SC. Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439 [Abstract] [Full Text] [Related]
32. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Ninomiya A, Imai M, Tashiro M, Odagiri T. Vaccine; 2007 May 04; 25(18):3554-60. PubMed ID: 17293015 [Abstract] [Full Text] [Related]
33. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Pyo HM, Masic A, Woldeab N, Embury-Hyatt C, Lin L, Shin YK, Song JY, Babiuk S, Zhou Y. Vaccine; 2012 Feb 08; 30(7):1297-304. PubMed ID: 22207090 [Abstract] [Full Text] [Related]
35. Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice. Wang Y, Li Q, Peng P, Zhang Q, Huang Y, Hu J, Hu Z, Liu X. Vet Microbiol; 2024 Jul 08; 294():110108. PubMed ID: 38729093 [Abstract] [Full Text] [Related]